A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).

Key facts

Study ID

NCT06811246

Run by

Merck Sharp & Dohme LLC

People needed

20

Starts

2024-02-07

Expected to finish

2024-07-14

Last updated by the study team

2025-02-06

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within 3 months prior to entering the study

Where it is running

• Celerion (Site 0001) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.